Considering the Discontinuation of Statins in Late-Stage Cancer Patients
May 31st 2014Patients starting palliative care for advanced cancer are often already on repeat prescriptions of statins to lower cholesterol and reduce risk of a heart attack or stroke, and many of these patients continue on statin therapy until death.
Read More
Obesity Increases Death Risk from Breast Cancer in Premenopausal Women with ER+ Disease
May 15th 2014Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease, according to findings from a large, retrospective study involving 80,000 patients.
Read More
Study Suggests Delaying ADT Until Symptoms Appear Following Primary Prostate Cancer Treatment
May 15th 2014A rising prostate-specific antigen (PSA) after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy (ADT), a large observational study has found.
Read More
Findings From Next-Generation Sequencing Offer Promise for New Breast Cancer Therapies
March 24th 2014The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Read More
Treatment Considerations for Younger Patients With Breast Cancer
March 13th 2014Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses treatment considerations for younger patients with breast cancer.
Read More
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
Patients With High PD-L1 Expression in mRCC are Less Sensitive to VEGF-Targeted Drugs
February 4th 2014According to a retrospective analysis of the phase III COMPARZ trial, high tumor expression of the protein PD-L1 (programmed cell death 1 ligand 1) is independently associated with shorter overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
Read More
Two New Drug Pairings are Active in Advanced and Refractory Urothelial Cancer, Studies Show
February 2nd 2014Investigators reported at the 2014 Genitourinary Cancers Symposium that two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.
Read More
Increased Use of Second-Line Therapies Has Not Improved Survival in Metastatic Urothelial Cancer
February 1st 2014Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.
Read More
A Biomarker Development Trial of Satraplatin in Patients With mCRPC
February 1st 2014William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Read More
Safety of Radium-223 in mCRPC Endures in Extended Follow-up
January 31st 2014Patients with bone metastatic castration-resistant prostate cancer (CRPC) who received radium-223 dichloride (Xofigo) continued to have a low incidence of myelosuppression and no associated secondary malignancies at a 1.5-year follow-up of the pivotal phase III ALSYMPCA study that was presented at the 2014 Genitourinary Cancers Symposium.
Read More
Abiraterone and Enzalutamide for mCRPC
January 31st 2014Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Read More
The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC
January 31st 2014Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.
Read More
Benefit for Radiotherapy/ Antiandrogen Combination Reinforced by Long-Term Data
January 30th 2014Improved outcomes continued to be demonstrated with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer, according to an updated analysis, conducted after 11 years of observation.
Read More